Tufts Center for the Study of Drug Development (CSDD) shared study results that indicate Quotient Sciences’ Translational Pharmaceutics platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. The Tufts CSDD study assessed development cycle times and their financial benefits by using data compiled on completed Translational Pharmaceutics projects to benchmark ag...